Kanabo Group Plc
KNB:LN
Overview
Company Profile
Kanabo Group Plc, is a leading developer and distributor of cannabis-derived products and inhalation technologies for medical patients and non-THC products for CBD consumers. Kanabo Group Plc was the first medicinal cannabis company to IPO on London Stock Exchange and is made up of supply- chain specialist subsidiaries, from cultivation consultancy to R&D to formula development and distribution, including:
Kanabo Agritec Ltd, a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo’s formulas and product line. Kanabo Research Ltd, a wholly owned subsidiary of Kanabo Group Plc, responsible for R&D, regulation, and quality assurance procedures. The GP Service – a Kanabo Group Plc owned, NHS approved online telehealth provider offering video consultations, online prescriptions, treatment forms and access to both Kanabo medical-cannabis & wellbeing CBD products.
Classification
Financials
Corporate
Board of Directors
David Tsur
Chairman, Non-Executive Director
Mr. Tsur is the Co-founder of Kamada Ltd, a public company listed on both the NASDAQ and Tel-Aviv Stock Exchange. He has served as its Chief Executive Officer and on its board of directors since the company’s inception in 1990, until July 2015. Currently he serves as Kamada’s Active Deputy Chairman of the Board. Prior to co-founding Kamada, Mr. Tsur was the Chief Executive Officer of Arad Systems and RAD Chemicals Inc. He has also held various positions in the Israeli Ministry of Economy (formerly named the Ministry of Industry and Trade), including Chief Economist and Commercial Attaché in Argentina and Iran. Mr. Tsur holds a BA degree in Economics and International Relations and a MBA in Business Management from the Hebrew University of Jerusalem.
Uzie Danino
Non-Executive Director
Mr. Danino has over 35 years of experience in the financial sector, including capital markets. Mr. Danino began his career at Bank Mizrahi in 1981 and worked in all of the bank’s business units filling a variety of managerial positions. In his last position with the bank, Mr. Danino served as the manager of customer asset division, which includes the bank’s investment management company. In 2012, Mr. Danino was appointed to head Excellence Investment House that at the time had NIS80 billion (approximately GBP 17 billion) in customer assets under management. In the framework of his position, he also serves as Chairperson of provident funds, trust funds, Stock Exchange Member Brokerage, and is a member of the Israeli Federation of Investment Houses. Today, Mr. Danino as a member and director of Rosario Capital, an underwriting company. In addition, Mr. Danino is a director in two public companies , namely UMI and Spacecom and serves a member of the University of Ariel Finance Committee.
Avihu Tamir
CEO, Executive Director
Mr. Tamir is a cannabis entrepreneur with five years hands-on experience in multiple cannabis ventures and has vast experience in consulting for international cannabis projects. Mr. Tamir began his career and built his reputation as a senior strategy consultant at Accenture. He is also the founder of Teva Nature, the leading vaporizer company in Israel. Mr. Tamir founded Kanabo Research in 2016 and since then has served as its CEO of the company. His expertise includes biotechnology, new agriculture and agro-tech, and other breakthrough technologies in the dynamic field of Medical Cannabis. Mr. Tamir holds a B.A. in Finance and Risk Management (Magna Cum Laude), and a M.A. in Political Science (Magna Cum Laude) from the IDC Herzliya.
Andy Morrison
Non-Executive Director
Formerly Chairman of Spinnaker Opportunities, Mr Morrison has focused on managing and developing junior public companies, largely in the energy sector including Xtract Energy Plc, Silvermere Energy Plc and Zeta Petroleum Plc, an ASX quoted firm with operations in Romania. He began his career at Shell in oil products and in 1999, joined BG Group Plc as a New Ventures Director. Subsequently he held senior New Business Development roles for the industrial gases group BOC Group Plc until its acquisition in 2007. Mr Morrison has a BSc in Chemical Engineering and Fuel Technology from the University of Sheffield and a Diploma in Company Direction from the Institute of Directors.
Gil Efron
Non-Executive Director
Mr. Efron is serving as President and Chief Financial Officer of NASDAQ and TASE dual-listed Purple Biotech Ltd., a clinical-stage company (PPBT) since June 2021, having previously held the position of Deputy Chief Executive Officer and Chief Financial Officer from October 2018. Prior to his current tenure at Purple Biotech, Gil served as Deputy CEO and CFO of Kamada Ltd., a NASDAQ and TASE dual-listed plasma-derived protein therapeutics company between 2011-2017. Mr. Efron holds a B.A. degree in Economics and Accounting and an M.A. degree in Business Administration from the Hebrew University of Jerusalem and was granted a certified public accountant’s license in Israel.